Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash | 9 | 11 | 6 | 4 | 3 | 3 | 4 | 6 | 7 | 6 | 7 | 9 | |||||
Assets Current | |||||||||||||||||
Assets Current | 9 | 11 | 6 | - | - | - | 4 | - | - | - | - | - | |||||
Finite Lived Intangible Assets Net | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 9 | 11 | 6 | 4 | 3 | 3 | 4 | 6 | 7 | 6 | 7 | 9 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable And Accrued Liabilities Current | 5 | 5 | 5 | 1 | 1 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | |||||
Deferred Compensation Liability Current | - | - | - | 0 | - | - | - | - | - | - | - | - | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 6 | 5 | 6 | 2 | 2 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | |||||
Deferred Compensation Liability Current And Noncur… | - | 1 | 1 | - | - | 0 | 0 | - | - | - | - | - | |||||
Employee Related Liabilities Current | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | 6 | 5 | 6 | 2 | 2 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital Common Stock | 100 | 98 | 87 | 80 | 75 | 71 | 69 | 63 | 61 | 58 | 57 | 56 | |||||
Stockholders Equity | 3 | 5 | 0 | 2 | 1 | 0 | 1 | 5 | 6 | 5 | 7 | 9 | |||||
Retained Earnings Accumulated Deficit | -97 | -93 | -87 | -78 | -73 | -69 | -68 | -58 | -55 | -53 | -50 | -48 | |||||
Liabilities And Stockholders Equity | 9 | 11 | 6 | 4 | 3 | 3 | 4 | 6 | 7 | 6 | 7 | 9 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Common Stock Shares Issued | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |||||
Shares Outstanding | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.35% | -45.16% | - | - | - | - | - | - | - | - | - | - |
| 2025 | -10.68% | 5.24% | 18.25% | -9.52% | -9.69% | -23.76% | 7.45% | 134.01% | 261.42% | -30.55% | -54.47% | - |
| 2024 | 12.84% | 19.50% | 3.36% | 11.62% | 5.77% | 3.46% | 0.52% | -5.22% | -4.78% | 5.36% | 7.93% | 12.07% |
| 2023 | - | - | - | -10.94% | -14.88% | 0.20% | 22.97% | 42.44% | 17.29% | -3.58% | 0.84% | 17.18% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Greenwich LifeSciences, Inc. (GLSI) — SEC Financial Statements & Analysis
Greenwich LifeSciences, Inc. (GLSI) is a pharmaceutical preparations company, incorporated in DE. Greenwich LifeSciences, Inc. trades on Nasdaq as: GLSI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Greenwich LifeSciences, Inc. reported a Debt-to-Equity ratio of 1.85x, a Price-to-Book (P/B) ratio of 110.05x (TTM), at a market cap of $343.01M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 1.85x
- P/B TTM
- 110.05x
- Market Cap
- $343.01M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Greenwich LifeSciences, Inc. in?
Greenwich LifeSciences, Inc. (GLSI) operates in the Pharmaceutical Preparations industry.
What is GLSI's market cap?
Greenwich LifeSciences, Inc. (GLSI) has a market capitalization of $343.01M as of 2026-06-30.
What exchange does GLSI trade on?
Greenwich LifeSciences, Inc. (GLSI) trades on the Nasdaq.
Where is Greenwich LifeSciences, Inc. incorporated?
Greenwich LifeSciences, Inc. is incorporated in DE.